Avidity Biosciences, Inc.

Covx Technology Ireland, Ltd.

Celmed Oncology (usa), Inc.

Covx Technologies Ireland Limited

Venkata Ramana Doppalapudi

Michael Caramian Cochran

Rob Burke

Andrew John Geall

Beatrice Diana Darimont

David Sai-Ho Chu

Barbora Malecova

Gulin Erdogan Marelius

Michael David Hood

Yunyu Shi

Rachel Elizabeth Johns

Palani Balu

Curt William Bradshaw

Hanhua Huang

Arthur A Levin

Joel Daniel Arias

Dingguo Liu

Abhijit Suresh Bhat

Jing-Yu Lai

Philip Kovach

Bin Liu

Gang Chen

Joel Desharnais

Yanwen Fu

Maria V Sergeeva

Bryan Douglas Oates

Usue Etxaniz Irigoien

Isaac Marks

Tyler Albin

Carlo Ballatore

John M Rizzo

Jing Yu Lai

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Compositions and methods of treating muscle dystrophy

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

Nucleic acid-polypeptide compositions and uses thereof

Disclosed herein are antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy that comprises administering antibody oligonucleotide conjugates or a pharmaceutical composition that induces alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping.

Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Compositions and methods of treating muscle atrophy and myotonic dystrophy

Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a disease which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

Una amidites and uses thereof

Disclosed herein, in certain embodiments, are anti-transferrin receptor antibodies, anti-transferrin receptor antibody conjugates, and pharmaceutical compositions which comprise the anti-transferrin receptor antibodies or conjugates. In some embodiments, also disclosed herein are methods of delivering a payload utilizing an anti-transferrin receptor antibody described herein, and methods of treatment with use of an anti-transferrin receptor antibody described herein.

Anti-transferrin receptor antibodies and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Venkata Ramana Doppalapudi